In the wake of the Covid-19 pandemic, unequal vaccine access has exposed the inequities perpetuated by the transnational industry that is corporate pharmaceuticals. Intellectual property rights catalyze the lack of production in low-income countries, leading to disproportionate vaccination rates in the global north. Yet lobbyists argue that intellectual property rights foster innovation of new drugs by billion-dollar pharma companies. A deep dive into access, pharmaceutical activity, profit margins, and IP law reveal some possible solutions to the access problem.
"Transnational Pharmaceuticals and COVID-19 Vaccines: Global Access,"
Undergraduate Journal of Global Citizenship: Vol. 5:
1, Article 5.
Available at: https://digitalcommons.fairfield.edu/jogc/vol5/iss1/5